FDA’s Pharmacy Compounding Advisory Committee has announced that it will hold two meetings (!) between now and year-end to consider recommending several bulk drug substances to the 503A Bulks List.
The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Seattle area October 3.
The final session of this year’s EduCon is coming up in just a few weeks, and it’s a special double helping of legal goodness.
We’ve added 31 Pharmacy-Facility Members since February!
There’s been plenty of coverage of Eli Lilly’s announcement this week that it will sell vials of Zepbound directly to consumers at a discount. But the company seems to have left out a few important caveats.
The Hill published an editorial by Dr. Kenneth McCall titled “Fake, unsafe weight-loss drugs are a worsening public health dilemma” in which he makes unfounded claims about pharmacy compounding. Here’s the response from our CEO.
We’ve added a new session to the Compounders on Capitol Hill lineup. Don’t miss the discussion of what’s on many a compounder’s (and regulators’ … and reporters’...) mind.
A big welcome to Ro, APC’s newest tier-level corporate patron!
For the fourth year in a row, USP will be holding a hybrid live/virtual workshop dedicated to improving the quality of compounding.
At least three issues affecting pharmacy compounding might be affected by the overturning of the decades-old “Chevron doctrine.”
FOLLOW US
